

Anti-CD3 Antibody (Visilizumab)

Introduction



Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used in the research of ulcerative colitis and Crohn's disease.

Product parameters

| Alternative Names | Visi, HUM-291 |
|----------------------|--|
| Target Accession | P07766 |
| Target | CD3 |
| CAS number | 219716-33-3 |
| Molecular Weight | 145 kDa |
| Host | СНО |
| Reactivity | Human |
| Conjugation | Unconjugated A P E X B TO |
| Form Achieve Perfect | Liquid Achieve Particetor, Explore the Unknown |
| Concentration | See label |
| Buffer System | 100 mM Pro 20 mM Arg pH 5.0. No preservative! |
| Clonality | Monoclonal |
| Purification | Protein A |
| Isotype | IgG2SA |
| Application | ELISA, FACS, Kinetics, Functional assay, Animal Model |
| Biological activity | - |
| Endotoxin | Less than 0.1 EU/ug determined by LAL method. |
| Sterilization | 0.2 μM filtered |
| Reconstitution | For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex. |
| Shipping | Dry ice |
| Storage | -80°C Usknown |
| Expiration Date | 2 years |
| Note | Please avoid freeze-thaw cycles. |

Note

1. This product is for scientific research use only.









